EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Amyloid‐related imaging abnormalities (ARIA) in anti‐amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup

Ellis S van Etten, Simin Mahinrad, Joshua D Grill, Stephen Salloway, Alireza Atri, Petrice M Cogswell, Tammie L S Benzinger, Takeshi Iwatsubo, Costantino Iadecola, Cynthia A Lemere, James A R Nicoll, Steven M Greenberg und 3 weitere

Alzheimer's & Dementia · 2026-04 · 22 (4)

DOI: 10.1002/alz.71361 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Alzheimer's & Dementia, online erschienen am 21.04.2026. Verfasst von Ellis S van Etten und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Alzheimer Disease, Brain, Neuroimaging, Amyloid beta-Peptides. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In 2011, a workgroup of the Alzheimer's Association Research Roundtable introduced recommendations for detecting and monitoring amyloid‐related imaging abnormalities (ARIA) in Alzheimer's disease (AD) clinical trials. Since then, anti‐amyloid immunotherapies have received regulatory approval for AD treatment and are beginning to enter clinical practice, underscoring the importance of informing healthcare providers, researchers, and patients about ARIA's implications in real‐world settings. In response, the Alzheimer's Association convened a new workgroup to review current knowledge of ARIA, including underlying mechanisms, clinical presentations, associated risk factors, mitigation strategies, radiologic detection methods, patients’ perspectives in treatment decision‐making, and outstanding challenges. Here, we outline key insights from this workgroup, highlighting that effective ARIA detection and monitoring in clinical practice requires adherence to robust protocols to mitigate risks and enhance patient safety. Limited availability of clinical and pathologic data on predictors of symptomatic and severe ARIA underscores the importance of continued real‐world data collection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseBrainNeuroimagingAmyloid beta-PeptidesHumansImmunotherapy

Stichwörter der Autor:innen

ARIAAlzheimer's diseaseamyloid‐related imaging abnormalitiesamyloid‐targeting therapiesanti‐amyloid therapiescerebral amyloid angiopathy

Substanzen

Amyloid beta-Peptides

Autor:innen und Institutionen

  • Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
  • Alzheimer's Association, Chicago, Illinois, USA.
  • Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, California, USA.
  • Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA.
  • Banner Sun Health Research Institute, Sun City, Arizona, USA.
  • Banner Alzheimer's Institute, Phoenix, Arizona, USA.

Förderung

  • NIA NIH HHS
  • NINDS NIH HHS
  • NIH HHS
  • ZonMw
  • Alzheimer Nederland
  • Alzheimer Research UK
  • National Institutes of Health

Zitieren

APA

van Etten, E. S., Mahinrad, S., Grill, J. D., Salloway, S., Atri, A., Cogswell, P. M., Benzinger, T. L. S., Iwatsubo, T., Iadecola, C., Lemere, C. A., Nicoll, J. A. R., Greenberg, S. M., Carrillo, M. C., Jack, C. R., & Sperling, R. A. (2026). Amyloid‐related imaging abnormalities (ARIA) in anti‐amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup. Alzheimer's & Dementia, 22(4). https://doi.org/10.1002/alz.71361

Vancouver

van Etten ES, Mahinrad S, Grill JD, Salloway S, Atri A, Cogswell PM, et al. Amyloid‐related imaging abnormalities (ARIA) in anti‐amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup. Alzheimer's & Dementia. 2026;22(4). doi:10.1002/alz.71361

BibTeX
@article{vanEtten2026,
  author = {van Etten, Ellis S and Mahinrad, Simin and Grill, Joshua D and Salloway, Stephen and Atri, Alireza and Cogswell, Petrice M and Benzinger, Tammie L S and Iwatsubo, Takeshi and Iadecola, Costantino and Lemere, Cynthia A and Nicoll, James A R and Greenberg, Steven M and Carrillo, Maria C and Jack, Clifford R and Sperling, Reisa A},
  title = {Amyloid‐related imaging abnormalities (ARIA) in anti‐amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  volume = {22},
  number = {4},
  doi = {10.1002/alz.71361}
}
Kostenlos starten →